Novo Holdings A/S’s Vaxcyte PCVX Stock Holding History

Novo Holdings A/S’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$46.5M	Sell	800,000 -60,000	-7%	-$3.26M	2.7%	14
2026 Q1	$50M	Sell	860,000 -56,160	-6%	-$3.05M	4.05%	9
2025 Q4	$42.3M	Hold	916,160	–	–	3.28%	12
2025 Q3	$33M	Hold	916,160	–	–	2.13%	16
2025 Q2	$29.8M	Buy	916,160 +1,160	+0.1%	+$38K	2.1%	17
2025 Q1	$34.6M	Buy	915,000 +165,000	+22%	+$13.2M	2.63%	13
2024 Q4	$61.4M	Hold	750,000	–	–	3.72%	9
2024 Q3	$85.7M	Sell	750,000 -200,000	-21%	-$18M	4.26%	8
2024 Q2	$71.7M	Buy	950,000 +105,000	+12%	+$7.15M	3.87%	8
2024 Q1	$57.7M	Hold	845,000	–	–	3.98%	6
2023 Q4	$53.1M	Hold	845,000	–	–	3.28%	10
2023 Q3	$43.1M	Hold	845,000	–	–	3.18%	11
2023 Q2	$42.2M	Buy	845,000 +100,000	+13%	+$4.74M	3.26%	11
2023 Q1	$27.9M	Buy	745,000 +20,000	+3%	+$848K	1.84%	18
2022 Q4	$34.8M	Sell	725,000 -98,705	-12%	-$3.87M	2.17%	16
2022 Q3	$19.8M	Hold	823,705	–	–	0.94%	23
2022 Q2	$17.9M	Buy	+823,705	New	+$19.1M	0.88%	21
2021 Q2	–	Sell	-416,937	Closed	-$8.23M	–	57
2021 Q1	$8.23M	Hold	416,937	–	–	0.34%	38
2020 Q4	$11.1M	Sell	416,937 -234,318	-36%	-$8.71M	0.47%	34
2020 Q3	$32.2M	Sell	651,255 -230,643	-26%	-$9.18M	1.6%	14
2020 Q2	$27.9M	Buy	+881,898	New	+$28.4M	1.8%	11

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Novo Holdings A/S's PCVX Position: Q2 2026 in Review

Novo Holdings A/S reduced its Vaxcyte (PCVX) stake by 7% in Q2 2026, selling an estimated $3.26M and leaving 800,000 shares worth $46.5M. The position accounts for 2.7% of the portfolio, ranked #14.

Novo Holdings A/S first reported a position in PCVX in Q2 2020 and has held it in 21 quarters since. The position peaked at $85.7M in Q3 2024. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

Novo Holdings A/S held 800,000 shares of Vaxcyte worth $46.5M as of Q2 2026.
Novo Holdings A/S sold 60,000 Vaxcyte shares in Q2 2026, an estimated $3.26M.
Vaxcyte made up 2.7% of Novo Holdings A/S's portfolio in Q2 2026, its #14 holding.
Novo Holdings A/S first reported a position in Vaxcyte in Q2 2020 and has held it in 21 quarters since.
Novo Holdings A/S's Vaxcyte position peaked at $85.7M in Q3 2024.
331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Novo Holdings A/S's 13F filing for Q2 2026, filed 14 Aug 2026.